← Back to Clinical Trials
Recruiting NCT06313827

NCT06313827 e-Health Program to Prevent Exacerbations in the Cystic Fibrosis Population

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06313827
Status Recruiting
Phase
Sponsor University of Valencia
Condition Cystic Fibrosis
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-10-01
Primary Completion 2026-01

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Exercise plus Monitoring Group (TG-2)Exercise plus monitoring and follow-up group (TGF-3)Exercise Group (CG-1)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-10-01 with a primary completion date of 2026-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to analyse the impact of a telematic assessment and monitoring protocol in people with cystic fibrosis, in order to identify exacerbations early, thus preventing loss of lung function and maintaining quality of life. Participants will be assigned to one of 3 study groups: Control group (CG-1): will receive their usual physiotherapy treatment; Treatment group (TG-2): will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment; Treatment and follow-up group (TGF-3): will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment, plus telematic control of exacerbations with feedback from the physiotherapist.

Eligibility Criteria

Inclusion Criteria: * Diagnosed cystic fibrosis * Family access to an internet-enabled device * Camera and microphone * Absence of exacerbations in the last 30 days Exclusion Criteria: * Patients with lung transplant or on the waiting list for lung transplantation * Previous eye surgery (3 months) * Hemothorax * Active infection or inflammatory process * Tumors * Cognitive problems that make it impossible for them to use telematic devices.

Contact & Investigator

Central Contact

Francisco Martinez-Arnau, PhD

✉ francisco.m.martinez@uv.es

📞 0034963983853

Frequently Asked Questions

Who can join the NCT06313827 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, studying Cystic Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06313827 currently recruiting?

Yes, NCT06313827 is actively recruiting participants. Contact the research team at francisco.m.martinez@uv.es for enrollment information.

Where is the NCT06313827 trial being conducted?

This trial is being conducted at Valencia, Spain.

Who is sponsoring the NCT06313827 clinical trial?

NCT06313827 is sponsored by University of Valencia. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology